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Abstract
Background and aims To assess work disability (WD)
rates in an inflammatory bowel disease (IBD) cohort
involving patients with Crohn’s disease (CD) or ulcerative
colitis (UC) cohort and to identify possible clinical or
demographic factors associated with WD. To our knowl-
edge, this is the first study from Eastern Europe that has
estimated indirect costs in IBD.
Methods Data from 443 (M/F: 202/241, CD/UC:
260/183, mean age: 35.5 (CD) and 40.5 (UC) years, bio-
logical drug exposure 31.2/11.5 %) consecutive patients
were included. WD data were collected by questionnaire
and the work productivity and activity impairment instru-
ment. Disability pension (DP) rates in the general popu-
lation were retrieved from public databases.
Results The overall DP rate in this IBD population was
32.3 %, with partial disability in 24.2 %. Of all DP events,
88.8 % were directly related to IBD. Overall, full DP was
more prevalent in IBD (RR: 1.51, p \ 0.001) and CD (RR:
1.74, p \ 0.001) but not in UC compared to the general
population and also in CD compared to UC (OR 1.57,
p = 0.03). RR for full DP was increased only in young CD
patients (RR\35 year olds: 9.4; RR36–40 year olds: 9.4 and 5.6,
p \ 0.01 for both). In CD, age group, previous surgery,
disease duration, frequent relapses, and the presence of
arthritis/arthralgia were associated with an increased risk
for DP. Among employed patients, absenteeism and pre-
senteeism was reported in of 25.9 and 60.3 % patients,
respectively, leading to a 28 % loss of work productivity
and a 32 % activity loss, and was associated with disease
activity and age group. Average cost of productivity loss
due to disability and sick leave with a human capital
approach was 1,450 and 430 €/patient/year in IBD,
respectively (total productivity loss 1,880 €/patient/year),
the costs of presenteeism were 2,605 (SD = 2,770) and
2,410 (SD = 2,970) €/patient/year in CD and UC,
respectively.
Conclusion Risk of DP was highly increased in young
CD patients (sixfold to ninefold). Previous surgery and
presence of arthritis/arthralgia was identified as risk factors
for DP. Work productivity is significantly impaired in IBD
and is associated with high productivity loss.
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Introduction
Inflammatory bowel diseases (IBD), including primarily
Crohn’s disease (CD) and ulcerative colitis (UC), are
chronic disabling gastrointestinal disorders with a variable
disease course, but the majority of the patients eventually
develop intestinal (penetrating or stricturing) or extrain-
testinal complications [1, 2].
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This chronic and potentially debilitating disease course
can represent a heavy burden for patients, impacting every
aspect of the affected individual’s life [3]. They account for
substantial direct and indirect costs to the health care system
and society. A large portion of the social costs associated
with IBD are indirect and are associated with temporary or
permanent work disability (WD) due to presenteeism, sick
leave, or disability pension (DP). All of these are increas-
ingly recognized as important negative outcomes.
In parallel, IBD treatment goals have evolved in the last
ten years, with the advent of biological therapy [4]. A
paradigm shift has occurred from merely treating symp-
tomatic disease, toward the prevention of disease compli-
cations in patients with unfavorable prognostic factors; the
latter being one of the main targets of current therapy. This
prophylactic methodology potentially prevents hospital-
izations and surgery [5], while also preserving quality of
life and working ability—both recognized as important
patient-centered outcome measures.
Work-disability rates of IBD patients vary considerably
in the literature, with rates between 5.3 and 27.1 %
reported [6–11]. Of note, the available studies were sub-
stantially different with regard to time periods, study
design, definitions of disability, geographic area and
patient cohorts. Additionally, there were differences in the
social-security systems influencing possibly not only
access to therapy but also employment and DP rates.
Importantly, most studies were conducted in the pre-bio-
logic era and very few studies included patient cohorts with
a high exposure to biological (anti-tumour necrosis factor-
alpha, anti-TNF) therapies [10].
Several factors have been associated with temporary or
permanent WD, including disease type [6, 9, 10], the activity or
presence of complications [10, 11], gender [8, 9, 12], age [9,
10], surgery [7, 10], hospitalisations [7], quality of life [7, 12],
and education level [6, 10]. In addition, only few studies out-
side clinical trials have assessed WD objectively by using
validated questionnaires such as the work productivity and
activity impairment (WPAI) instrument [13, 14]. Data are
missing from Eastern Europe. The aim of the present study was
to assess the DP and WD rates in an IBD cohort treated in two
IBD biological centers in Hungary, with easy access and high
exposure to anti-TNF therapy. In addition, we sought to esti-
mate the costs of productivity loss in IBD and identify possible
clinical or demographic factors associated with DP and WD.
Patients and methods
Patients
Four hundred and forty-three consecutive patients treated
with IBD (M/F 202/241, CD/UC: 260/183, mean age at
onset: 26.3 (SD = 11.2) and 30.0 (SD = 13.0) years,
duration: 9.2 (SD = 7.1) and 9.9 (SD = 9.7) years with at
least 1-year disease with complete clinical follow-up were
included from two specialized IBD centers providing bio-
logical therapy in Hungary. The clinical characteristics are
presented in Table 1.
Methods
Diagnosis was based on the Lennard-Jones criteria [15].
Disease phenotype (age at onset, duration, location, and
behavior) was determined according to the Montreal clas-
sification [16]. Medical records, including data regarding
the presence of major extraintestinal manifestations (EIM),
previous frequency of flare-ups (frequent flare-up: [1
Table 1 Clinical characteristics of patients with IBD
Characteristics CD UC
n 260 183
M/F 122/138 80/103
Age at presentation (years)* 26.3
(11.2)
30.0
(13.0)
Age at assessment (years)* 35.7
(11.3)
40.7
(14.1)
Disease duration (years)* 9.2 (7.1) 9.9 (9.7)
Location**
L1 16.9 % NA
L2 33.1 %
L3 48.8 %
L4 only 1.2 %
L4 7.3 %
Extent at diagnosis
Proctitis NA 9.9 %
Left-sided 48.9 %
Extensive 41.2 %
Behavior at diagnosis***
B1 36.9 % NA
B2 24.6 %
B3 38.5 %
Perianal disease 34.6 % NA
Arthritis/arthralgia 34.6 % 24.6 %
Azathioprine therapy 64.3 % 36.3 %
Biological therapy 31.2 % 11.5 %
Resection/re-operation in CD or colectomy
in UC
41.1/
32.7 %
8.3 %
NA not applicable
* Mean (SD)
** Classification of CD by location of the disease: L1, terminal ileum;
L2, colon; L3, ileocolonic disease L4: upper GI involvement
*** Classification of CD by disease behavior: B1, inflammatory
phenotype without stricture formation and penetrating disease; B2,
stricturing disease; B3, penetrating disease
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clinical relapse/year [17]), previous surgical procedures
(resections or perianal procedures), the presence of familial
IBD, smoking habits, and perianal involvement, were
determined by a thorough review of the patients’ medical
charts, which had been collected in a uniform format.
Previous and concomitant medical therapy (steroid or
immunosuppressive, previous biological therapy) and
actual disease activity (in CD the Crohn’s Disease Activity
Index (CDAI [18]) and Harvey–Bradshaw Index (HBI
[19]), and in UC the Colitis Activity Index (CAI or MAYO
score [20]) were meticulously registered parallel with the
administration of the questionnaires. Both centers were
monitored for quality of care and regulation compliance by
the National Health Insurance Fund Administration (Ors-
za´gos Ege´szse´gbiztosı´ta´si Pe´nzta´r, OEP) in June 2011.
Work disability data were collected by a questionnaire
from September 2012 to September 2013. Questions
included full or partial DP, actual and previous employ-
ment, unemployment and the WPAI questionnaire V2 for
CD and UC [21, 22]. From 2012 the Hungarian pension
system grants two types of subsidies for disabled patients:
full DP (disability subsidy) and a temporary partial DP
(rehabilitation subsidy), as assessed by the Hungarian
Central Administration of National Pension Insurance
(Orsza´gos Nyugdı´jbiztosı´ta´si F}oigazgato´sa´g, ONYF). Data
on full DP in the background population were retrieved
from public databases (ONYF) [23, 24]. The 2010 national
full DP rates (total and both gender and age-group specific
rates were available) were used for comparison.
The central coordination and database management was
completed at the 1st Department of Internal Medicine,
Semmelweis University (by MDM, BDL and PLL). The
study was approved by the Semmelweis University
Regional and Institutional Committee of Science and
Research Ethics (117/2012).
Statistical methods
Descriptive statistics were calculated and variables were
tested for normality using Shapiro–Wilk’s W-test. The v2-
test and v2-test with Yates correction and logistic regres-
sion analysis were used to assess the association between
categorical clinical variables, and DP. The Mann–Whitney
U-test, Spearman Rank Order correlation and the Kruskal–
Wallis test were used to test the association between cat-
egorical variables, disease activity, and WPAI. Kaplan–
Meier survival curves were plotted to determine probability
of full DP.
We calculated the productivity loss due to disability
with the human capital approach and friction cost method
[25, 26], the productivity loss due to sick leave, the total
productivity loss and the cost of presenteeism. For calcu-
lating disability-related productivity loss, we multiplied the
number of missed months due to disability per patient by
the average monthly gross salary We didn’t distinguish full
and partial disability in neither methods. The maximum
calculated duration in human capital approach and friction
cost method were 12 and six months, respectively. For
calculating sick-related costs, we multiplied the average
missed working hours/patient/week by the average gross
hourly wage and the number of weeks in a year. The total
productivity loss is the sum of these two components. For
the estimation of the cost of presenteeism [27], we multi-
plied the average hours worked per week by the presen-
teeism score. The resulting lost hours due to presenteeism
were multiplied by the average gross hourly wage and the
number of weeks in a year. Data were retrieved from the
databases of the Hungarian Central Statistical Office (KSH)
for calculating the Hungarian average monthly gross salary
and average gross hourly wage in 2013, including
employment taxes (1.001 and 5.96 €, respectively). We
assumed a maximum 40 h working week. The official
Hungarian retirement ages (62 years for both genders)
were used for the calculation. For currency conversion
300HUF = 1€ was assumed. Variables with p \ 0.1 were
included in multivariate testing. A p value \0.05 was
considered significant. For statistical analysis, SPSS 20.0
was used.
Results
The patient characteristics are consistent with the previ-
ous IBD center-based cohorts (Table 1). The mean dis-
ease duration was 9–10 years. Almost 50 % of CD
patients had extensive disease, and a complicated phe-
notype was observed in 63.1 %, while perianal involve-
ment was observed in 34.6 %. Consequently, the need for
immunosuppressives (64.3 %) or anti-TNFs (31.2 %) was
frequent. At the time of the assessment 28.5 % of patients
had active disease (CDAI [ 150), while 15.2 % of
patients had moderate-to-severe disease activity
(CDAI [ 220) with a mean CDAI of 113 (SD = 125) and
HBI of 3.6 (SD 3.8). Similarly, in UC more than 41 % of
patients had extensive location with a frequent use of
immunosuppressives (36.3 %) or anti-TNFs (11.5 %). At
the time of the assessment 24.6 % of patients had active
disease with a mean partial Mayo score (pMAYO [ 3) of
2.3 (SD 2.6).
Frequency of and risk factors for disability pension
The overall DP rate in this IBD population was 32.3 %
with partial DP in 24.2 %. Of all DP events, 88.8 % were
directly related to IBD. Of those patients with DP, 79 %
(77.8 % with full DP) did work before the DP. For those
DP and WD in IBD S123
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patients with partial- or full-DP, 63.5 and 32.2 %, respec-
tively, felt that they could work. Fifty percent of patients
with partial DP had a part time job. The probability of full
DP in IBD at 5, 10, and 15 years from diagnosis was 6.0,
9.1 and 12.1 %, respectively, while in CD it was 6.2, 9.7
and 15.0 % (Fig. 1). Overall, full DP was more prevalent in
IBD (8.1 %, RR: 1.51, p = 0.016) and CD (9.2 %,
p = 0.009) but not in UC (6.6 %, p = 0.56) compared to
the background population (5.5 %). The full DP rate was
higher in CD compared to UC (OR 1.57, 95 % CI 1.04-
2.38, p = 0.038). The partial and full DP rates in IBD
increased gradually parallel with the age groups (from
17.7 % in the \35-year-olds to 59.6 % in the 51–62 year-
olds). The RR for full DP was highest in patients with an
age \35 years and 36–40 years (RR: 9.4 and 5.6,
p \ 0.01), while patients over 46 years of age had no
increased RR (Table 2). In a sensitivity analysis, DP cases
not related to IBD were excluded. All associations
remained the same in both IBD (RRIBD\35 years: 9.4, 95 %
CI 4.5–19.5, RRIBD36–40 years: 4.8, 95 % CI 2.1–10.9,
RRIBD41–45 years: 4.4, 95 % CI 1.7–11.3, p B 0.001 for all)
and CD patients (RR-s were unchanged for patients
younger than 46 years old).
In CD, age group (p \ 0.001), previous surgery or
colectomy (OR 4.48, 95 % CI 2.86–7.02), long disease
duration (OR 3.06, 95 % CI 2.02–4.62), frequent relapses
(OR 1.59; 95 % CI 1.03–2.46) and the presence of arthritis
or arthralgia (OR 3.66, 95 % CI 2.37–5.64) but not disease
phenotype, exposure to steroids, or the need for
azathioprine or biological were associated with increased
risk for DP in univariate analysis. The association for age
group, previous surgery and arthritis or arthralgia remained
significant in a logistic regression analysis (Table 3).
Work productivity and activity impairment
in inflammatory bowel diseases
We calculated productivity loss outcomes in the 212 full-
time or part-time employed patients. Overall, absenteeism
and presenteeism was reported in 25.9 % and 60.3 %
patients, respectively. Absenteeism [8.5 % (SD 22.8 %)
and 11.7 % (SD 26.1 %)], presenteeism [27.6 % (SD
28.1 %) and 24.5 % (SD 28.4 %)], activity loss [33.9 %
(SD 29.4 %) and 31.0 % (SD 31.2 %)] and work produc-
tivity loss [28.8 % (SD 29.4 %) and 27.6 % (SD 31.8 %)]
as assessed by missing days was not different in CD and
UC patients. In contrast, it was significantly different
according to IBD activity (26.9 % of IBD patients reported
IBD activity at WPAI assessment according to CDAI or
partial Mayo score, Fig. 2) in all patients as well as in CD
and in UC separately (data not shown). Similarly, previous
surgery or colectomy was associated with all parameters
Table 2 The frequency and risk for disability pension (DP) accord-
ing to the age groups in inflammatory bowel diseases (IBD) and
Crohn’s disease (CD) compared to the gender and age-matched
background population
Age
groups
Total DP
(%)
Full DP
(%)
ORb for full DP
(95 % CI)b
IBD
18–35 17.7 3.5 9.41 (4.54–19.5)#
36–40 33.7 8.2 5.60 (2.75–11.4)#
41–45 54.8 14.3 5.28 (2.52–11.1)#
46–50 38.7 6.5 1.25 (0.33–4.76
51–62 59.6 21.0 1.34 (0.81–2.21)
CD
18–35 21.6 4.5 12.2 (5.59–26.7)#
36–40 45.3 11.3 7.79 (3.67–16.6)#
41–45 68.0 20.0 7.4 (3.38–16.2)#
46–50 46.7 13.3 1.29 (0.19–8.56)
51–62 52.0 24.0 1.54 (0.76–3.08)
All of the frequency and risk values are negative in subgroup UC
# p \ 0.001
a Odds-ratio
b vs controls
Fig. 1 Frequency of full disability pension (DP) in Crohn’s disease
(CD) according to disease duration
Table 3 Factors associated with DP in patients with CD in logistic
regression analysis
p Odds ratio 95 % CI
Age decade \0.001 1.47 1.22–1.77
Long ([10 years) disease duration 0.07 1.66 0.96–2.85
Frequent ([1/year) relapses 0.18 1.44 0.84–2.47
Arthritis/arthralgia \0.001 3.41 1.98–5.89
Previous surgery \0.001 5.40 3.10–9.41
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(pabsenteeism = 0.003, ppresenteeism = 0.04, pactivity loss =
0.06 and pwork productivity loss = 0.026) (Table 4).
In addition, presenteeism (p = 0.03) and activity loss
(p \ 0.001) was associated with age groups by Kruskal–
Wallis test as well as presenteeism (p = 0.001 for both).
Activity loss (p \ 0.001) and work productivity loss
(p = 0.02 and p = 0.001) were associated with long dis-
ease duration and presence of arthritis/arthralgia.
Productivity loss due to disability and sick leave,
the cost of presenteeism
The average cost of productivity loss due to disability with
human capital approach was 1,450 (SD = 3,905) €/patient/
year in IBD. In CD, the cost was 1,545 (SD = 4,010) €/
patient/year, while it was 1,310 (SD = 3,740) €/patient/
year in UC. There was no significant difference between
the two subgroups (p = 0.505). We calculated the pro-
ductivity loss due to disability with the friction cost method
as well. Only one patient became eligible for DP in the last
six months before data collection. Due to this, the average
cost was 11.3 (SD = 240) €/patient/year. The average
number of missed working hours was 1.39 (SD = 5.87)
hours/patient/week and the average cost of productivity
loss due to sick leave was 430 (SD = 1,820) €/patient/year
in IBD. The number of missed working hours in CD and
UC were mean 1.28 (SD = 5.64) and 1.56 (SD = 6.20)
hours/patient/week, leading to sick-leave related costs of
mean 395 (SD = 1,750) and 485 (SD = 1,920) €/patient/
year, respectively. There was no significant difference in
sick-leave related costs between the two subgroups
(p = 0.576).
The total productivity loss with the human capital
approach was 1,880 (SD = 4,310) €/patient/year in IBD. In
CD, the total productivity loss was 1,940 (SD = 4,375) €/
patient/year, while it was 1,795 (SD = 4,220) €/patient/
year in UC. The total productivity loss with the friction
cost method was 445 (SD = 1,835) €/patient/year in IBD.
The average hours worked in CD and UC were 30.42
(SD = 13.84) and 31.73 (SD = 13.24) hours/patient/week,
respectively. The lost hours due to presenteeism were mean
8.40 (SD = 8.93) and 7.77 (SD = 9.58) hours/patient/
week, while the costs of presenteeism were 2,605
(SD = 2,770) and 2,410 (SD = 2,970) €/patient/year in
CD and UC, respectively. There was no significant dif-
ference between the two subgroups (p = 0.455).
Discussion
The main finding of the present study was a sixfold to
ninefold increased risk for DP in young patients CD despite
easy access and high percentage of biological therapy in
these patients in this consecutive IBD cohort treated in
specialized IBD centers. In addition, absenteeism and
presenteeism were frequent among full or part time
employed patients (25.9 % and 60.3 % respectively) with
the latter becoming more common with age. Besides age,
factors associated with DP or WD were previous surgery,
long disease duration, and arthralgias/arthritis.
Full and partial DP rates identified in our study were, to
some extent, different from recent reports from Europe and
North America. In one of the landmark population-based
study from the IBSEN cohort [9], the frequency of full DP
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Fig. 2 Absenteeism, presenteeism, activity loss and work productiv-
ity loss according to the disease activity in patients with IBD
Table 4 Correlation between absenteeism, presenteeism, activity loss, work productivity loss and disease activity in Crohn’s disease (CD) and
ulcerative colitis (UC)
CD UC
CDAI index HBI index pMayo index
Coefficient p value Coefficient p value Coefficient p value
Absenteeism 0.22 0.01 0.35 \0.001 0.45 \0.001
Presenteeism 0.21 0.007 0.39 \0.001 0.51 \0.001
Activity loss 0.36 \0.001 0.39 \0.001 0.37 \0.001
Work productivity loss 0.30 \0.001 0.48 \0.001 0.60 \0.001
Spearman Rank Order correlation, CDAI Crohn’s disease activity index, HBI: Harvey–Bradshaw index, pMAYO partial Mayo score
DP and WD in IBD S125
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was 18.8 % in IBD after 10-years’ disease duration in 518
patients during follow-up. The DP rate was 8.5 % in an
earlier report after five years [8]. Rates were not different
in CD and UC, but an approximately twofold risk was
reported in females, and was even higher in patients
receiving steroids 1-year after diagnosis. However, this
cohort dated back to the pre-biologic era, with only very
limited biologic exposure. Interestingly, the rate of full-DP
unrelated to IBD was exceedingly high in UC. Felative
risks for UC related DP rates were not calculated.
Somewhat contrastingly, in a report from the South
Limburg cohort in 2000 [6], authors reported a 13 % and
24 % risk for full DP in UC and CD, respectively, with an
8–14 % partial-DP rate after a median 7 years’ disease
duration in 680 IBD patients. Rates in this cohort were
similar in males and females, but were associated with
young age at onset and higher educational level. DP rates
were lower in a recent nationwide IBD cohort (n = 2,282)
from the Netherlands [10]. In this cohort, patients had a
high exposure to biologicals (CD: 33.3 % and UC: 9.5 %),
and reported full-DP or partial-DP rates were 18.8 % and
8 %, respectively, in CD, and 9.5 % and 5.4 %, respec-
tively, in UC after median disease duration of 16 and
14 years. Overall, RR was increased over the background
population. Factors associated with DP were higher age,
low education, depression, chronic back pain, joint mani-
festations and disease-related risk factors such as pene-
trating disease phenotype. In addition, steroid use was
associated with DP in UC.
In the present study, in a CD cohort with similar high
exposure to anti-TNFs, the probability of full DP was
increased only in CD, with a cumulative probability of 9.7
% and 15 %, respectively, at ten and 15 years from diag-
nosis. Both partial-DP and full-DP rates increased with age.
In contrast, the relative risk of DP was increased only in
patients younger than 46 years of age, and was associated
with previous surgery and arthritis/arthralgia, but not
gender, disease phenotype, exposure to steroids, immuno-
suppressives or anti-TNFs. A similar age-dependent
increase in disability rates was also reported in the IBSEN
cohort and a recent report from the Swiss IBD cohort [11].
In the latter, DP rates increased from 2 % to 23 % in CD
and from 3 % to 7 % in UC in the [25–35 to [55 years-
olds in the 1,187 patients after a median of ten and
seven years of follow-up, respectively.
Similar rates were recently reported from the Manitoba
IBD cohort from Canada [14]. WD rates were 19 % in CD
and 11 % in UC (p \ 0.05), as assessed by the Work and
Social Adjustment Scale (WSAS). Disability was associ-
ated with long-term active disease and depression but not
IBD-related surgeries or hospitalizations. Finally, only a
5.3 % permanent WD rate was reported from an IBD
center cohort (n = 737, duration 13.8 years) from the US
[7]. Patients reporting low quality of life (OR 12.4), or
requiring multiple surgeries (OR 7.09) or hospitalizations
(OR 2.76) were identified to be at risk for CD-related WD
in a subcohort of 185 patients.
Significantly, less data are available on temporary WD
in IBD outside clinical trials. In addition, most studies had
only a semiquantitative assessment of WD. Earlier studies
reported an association between overall WD, employment
status and quality of life (HRQL and SF36) [8, 12]. In a
recent study by the Swiss group, authors investigated fre-
quency and predictors of temporary WD. Temporary WD
was reported in one-fifth of IBD patients at enrollment
(median disease duration of ten years in CD and seven -
years in UC) and in 12–13 % during the 13-month pro-
spective follow-up. Predictors for days absent and
temporary WD in CD were gender, disease duration, dis-
ease activity, C-reactive protein level, smoking, depres-
sion, presence of fistulas, EIM, and the use of
immunosuppressants or steroids. In UC it was associated
with gender, age, disease duration, disease activity, and the
use steroids or antibiotics. In addition, in a very recent
Australian study [13], authors assessed healthcare utiliza-
tion, cost, and work-related impairment in patients with
UC. Similar to the present study, WD was determined by
the WPAI questionnaire. WPAI was associated with qual-
ity of life assessed by Assessment of Quality of Life—8-
Dimension (AqoL-8D), EuroQol 5-dimension, 5-level
(EQ-5D-5L), the disease-specific Inflammatory Bowel
Disease Questionnaire (IBDQ). In concordance with pre-
vious studies, quality-of-life measures were associated with
disease severity. In addition, disease activity was identified
as the main driver of health care costs and the predictor for
impairment in work productivity and daily activities. Of
note, the close correlation between WPAI and disease
activity suggests that WPAI assessment can be used as a
patient reported activity measure. Overall, UC patients
reported substantial UC-related impairment on all four
categories of the WPAI, with the greatest level of impair-
ment (30.9 %) in daily activities other than work. In con-
trast, mild disease activity was associated with moderate
impairment only. Similarly, disease activity was identified
as the main predictor for all four items of the WPAI.
However, in contrast to the previous study we failed to
identify significant differences in the WPAI outcomes
between mild and moderate-to-severe patients in either UC
(pMayo mild = 3–4, moderate to severe[4) or CD (CDAI
mild: 151–220, moderate to severe [220), however, both
were significantly different from the patients in remission
(p \ 0.02 for presenteeism, work productivity loss and
activity loss in CD and p \ 0.01 for all comparisons for
UC by Mann–Whitney U test between patients in remission
and different disease activity and p \ 0.001 by Kruskal–
Wallis test for the whole group).
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This is the first time that costs for productivity loss in
IBD have been estimated from an Eastern European
country. Average cost of productivity loss due to disability
and sick leave with human capital approach was 1,450 and
430 €/patient/year, respectively, (total productivity loss
was 1,880 €/patient/year, which represents a high eco-
nomic burden, especially compared to the monthly gross
salary. These figures are comparable from that reported in
other chronic inflammatory diseases, e.g., psoriatic arthritis
(PsA) or rheumatoid arthritis (RA) from the same region or
compared to the monthly gross salaries. For instance, in
Hungary, the total indirect cost was 2,660 €/patient/year in
PsA, 4,240 €/patient/year in RA, whilst in the Netherlands
productivity loss of RA was 5,545 €/patient/year and 8,605
€/patient/year in Finland (costs were recalculated with
prices from 2013 and with the actual exchange rates for the
comparison) [28–33].
The authors are aware of possible limitations of the
present study. The study investigated a referral IBD pop-
ulation treated in two specialized IBD centers and results
may not be generalizable to population-based and non-IBD
center cohorts. In addition, some possible confounders
(e.g., highest education level) were not assessed, as there
was a change in the reimbursement policy of anti-TNFs in
Hungary in 2008. After 2008, the anti-TNF use has become
more widespread with easier and earlier use in CD and UC
patients with poor prognostic factors. However, in the
present cohort, a significant proportion of patients may
have received anti-TNFs according to the earlier reim-
bursement strategy only at a later disease stage, thereby the
therapeutic approach was suboptimal. This may have
influenced the association between anti-TNFs and the DP
outcome. In contrast, the strengths of this study include
vigorous prospective data collection and a detailed defini-
tion of the clinical phenotypes. In addition, the centers
included apply an accelerated treatment and monitoring
strategy in IBD patients and so the step-up to anti-TNFs is
far quicker compared to community centers. Our calcula-
tion likely overestimates the actual cost of presenteeism,
due to lack of standardization of evaluation of productivity
costs we have to be very cautious in the interpretation of
these results [34], and further research is needed.
In conclusion, in this contemporary IBD cohort with a
high exposure to anti-TNFs, the risk of DP was highly
increased in only young CD patients (sixfold to ninefold).
Previous surgery and presence of arthritis/arthralgia was
identified as risk factor for DP. Work productivity is sig-
nificantly impaired in IBD, and it is associated with age
and disease activity.
Conflict of interest The authors do not have any competing
interest.
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